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A bs tr ac t
Background
The interleukin-2–mediated immune response is critical for host defense against 
infectious pathogens. Cytokine-inducible SRC homology 2 (SH2) domain protein 
(CISH), a suppressor of cytokine signaling, controls interleukin-2 signaling.
Methods
Using a case–control design, we tested for an association between CISH polymor-
phisms and susceptibility to major infectious diseases (bacteremia, tuberculosis, and 
severe malaria) in blood samples from 8402 persons in Gambia, Hong Kong, Kenya, 
Malawi, and Vietnam. We had previously tested 20 other immune-related genes in 
one or more of these sample collections.
Results
We observed associations between variant alleles of multiple CISH polymorphisms 
and increased susceptibility to each infectious disease in each of the study popu-
lations. When all five single-nucleotide polymorphisms (SNPs) (at positions −639, 
−292, −163, +1320, and +3415 [all relative to CISH]) within the CISH-associated locus 
were considered together in a multiple-SNP score, we found an association between 
CISH genetic variants and susceptibility to bacteremia, malaria, and tuberculosis 
(P = 3.8×10−11 for all comparisons), with −292 accounting for most of the associa-
tion signal (P = 4.58×10−7). Peripheral-blood mononuclear cells obtained from adult 
subjects carrying the −292 variant, as compared with wild-type cells, showed a 
muted response to the stimulation of interleukin-2 production — that is, 25 to 40% 
less CISH expression.
Conclusions
Variants of CISH are associated with susceptibility to diseases caused by diverse 
infectious pathogens, suggesting that negative regulators of cytokine signaling 
have a role in immunity against various infectious diseases. The overall risk of one 
of these infectious diseases was increased by at least 18% among persons carrying 
the variant CISH alleles.
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Tuberculosis, malaria, and invasive bacterial disease together account for more than 5 million deaths annually in the de-
veloping world. Although a significant propor-
tion of interindividual variation in disease sus-
ceptibility can be attributed to environmental 
factors such as malnutrition and infection with 
the human immunodeficiency virus (HIV), a sub-
stantial portion is unexplained. Comparative stud-
ies involving twins and adopted persons suggest 
a genetic component,1 and genes that, when mu-
tated, result in primary immunodeficiency states 
have been identified. Such immunodeficiencies are 
extremely rare, however, and the current under-
standing of common host genetic factors influ-
encing susceptibility to major infectious diseases 
at the population level is limited.
A principal feature of the host immune re-
sponse to infection by structurally diverse patho-
gens is the inflammatory cytokine response.2-4 
The proinflammatory cytokine interleukin-2 de-
termines the magnitude and duration of the T-cell 
response immediately after antigen encounter5 
and assists in the maturation of macrophages 
and the proliferation of B cells and natural killer 
cells6 in the early stages of the adaptive immune 
response. Interleukin-2 also regulates the evolu-
tion of memory T cells after resolution of infec-
tion.7 An excessive cytokine-mediated inflamma-
tory response can be harmful to the host, resulting 
in severe forms of malaria and sepsis.8-11
Control of cytokine signaling in humans is 
mediated in part by negative feedback from the 
suppressor of cytokine signaling (SOCS) family 
of proteins. Cytokine-inducible SRC homology 2 
(SH2) domain protein (CISH) was the first mem-
ber of the SOCS family to be described.12,13 CISH 
is the gene most consistently up-regulated by 
interleukin-2 stimulation in humans,14 and it ap-
pears to be critical for T-cell proliferation and 
survival15 in response to infection. CISH controls 
the signaling of a variety of cytokines, in particu-
lar interleukin-2. Unlike the other members of 
the SOCS family, CISH binds to the phosphory-
lated tyrosine residues of cytokine receptors and 
masks sites at which the signal transducer and 
activator of transcription 5 (STAT5) would other-
wise dock.12,16-19 Thus, increased CISH activity 
blocks the cytoplasmic docking and activation of 
STAT5 and thereby inhibits downstream cyto-
kine signaling. Given the central role of CISH in 
controlling interleukin-2 signaling, we hypothe-
sized that variation in CISH influences suscepti-
bility to common infectious diseases.
Me thods
Subjects
We analyzed data on 8402 persons from seven 
case–control series (Table 1). These persons in-
cluded Kenyan children with bacteremia20; per-
sons with tuberculosis from Malawi,21 Hong 
Kong,22 and Gambia23; and persons with severe 
malaria from Gambia,24 Kenya,25 and Vietnam.8 
We obtained written informed consent from the 
study participants or their parents or guardians 
and ethics approval from the relevant national 
authorities for all study collections (see the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org). We obtained blood 
samples from which we extracted DNA (see the 
Supplementary Appendix). Controls were geo-
graphically matched to the cases. Twenty other 
immune-related genes have been studied previ-
ously in one or more of these sample collections 
(see the Supplementary Appendix).
Genotyping, Cell Stimulation, and Gene 
Expression
We used standard methods for genotyping (see 
the Supplementary Appendix). We purified pe-
ripheral-blood mononuclear cells (PBMCs) from 
whole blood obtained from the subjects, cultured 
these cells, and then stimulated them with inter-
leukin-2 or interleukin-3. We harvested the PBMCs 
at 0, 30, 60, and 120 minutes after the addition of 
interleukin; extracted RNA using a standard 
method; and synthesized and assayed comple-
mentary DNA using a real-time polymerase-
chain-reaction assay (Supplementary Appendix).
Statistical Analysis
Power calculations for all case–control studies are 
included in Figure 1 in the Supplementary Ap-
pendix. A comparison of allele frequencies accord-
ing to the different genetic patterns of inheri-
tance between case subjects and controls was 
performed with Pearson’s chi-square test. The 
most likely pattern of inheritance was deter-
mined on the basis of the best-fitting model with 
the use of logistic regression. Detailed descrip-
tions of the statistical procedures, as well as of 
the various patterns of inheritance, are included 
in the Supplementary Appendix. Analysis of pair-
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wise linkage disequilibrium between single-
nucleotide polymorphisms (SNPs) was performed 
with the use of the r 2 algorithm in Haploview 
software, version 3.2.26 The multiple-SNP score 
was analyzed as previously described for case–
control populations.27 Subjects were classified 
according to the number of risk alleles they car-
ried (0, 1, 2, 3, or ≥4). A trend test for association 
was then performed.28 Our analysis of gene- 
expression data is included in the Supplementary 
Appendix.
R esult s
Genetic Analysis of CISH
CISH comprises four exons, of which exons 2 to 
4 encode the CISH protein. We sequenced CISH 
(1000 bp upstream of the transcription start to 
the end of exon 4, including introns) in 24 case 
subjects and 24 controls from the Kenyan Bac-
teremia Study. The power to detect SNPs with a 
minor-allele frequency of 0.05 was 99.3% (Fig. 2 in 
the Supplementary Appendix). We identified eight 
SNPs with a minor-allele frequency greater than 
5% (Fig. 3A in the Supplementary Appendix), and 
we did not detect any new coding changes or 
predicted splice-junction variants. We then geno-
typed these eight SNPs in the case–control Ken-
yan Bacteremia Study. Four of these SNPs (at posi-
tions −639, −292, −163, and +3415) showed 
evidence of association (P = 0.02 to P = 1.0×10−3) 
(Fig. 1 and Table 2); the variant alleles at each 
SNP were associated with an increased suscepti-
bility to bacteremia. Adjustment for HIV status, 
malnutrition, and age did not significantly affect 
these associations.
We observed low pairwise linkage disequilib-
rium between SNPs at positions −639 and +3415, 
between these SNPs and those that lie between 
them, and between the SNPs that lie between 
them (r2<0.50) (Fig. 3B in the Supplementary 
Appendix). We also observed associations be-
tween multiple SNPs and susceptibility to disease, 
and bearing in mind the low pairwise linkage 
disequilibrium between these SNPs, we hypothe-
sized that the risk alleles at these SNPs confer 
susceptibility independently of one another. To 
investigate whether the risk of disease increased 
in an allele dose-dependent manner with respect 
to the number of risk alleles, we determined 
multiple-SNP scores for the five SNPs.26 We ob-
served that the risk of bacteremia was propor-
tionate to the number of risk alleles carried 
(P = 5.1×10−5) (see the Supplementary Appen-
dix). The haplotype analysis was uninformative, 
presumably because of the low intermarker link-
age disequilibrium. We did not observe any sig-
nificant interaction among the five SNPs, and 
we went on to genotype them in the remaining 
six case–control studies.
In the Malawian Tuberculosis Study, the minor 
alleles of three SNPs (−292, +1320, and +3415) 
were associated with increased susceptibility to 
tuberculosis (P = 0.01 to P = 5.0×10−3) (Fig. 1 and 
Table 2). For +1320 (P = 6.0×10−3), the effect of 
the risk allele appeared to be strongest with a 
recessive pattern of inheritance. Persons who 
were homozygous for the risk allele were sig-
nificantly more susceptible to tuberculosis than 
matched controls (5.6% of case subjects were 
homozygous for the risk allele, as compared 
with 1.9% of controls; P = 5.0×10−3). Adjustment 
Table 1. Characteristics of the 8402 Subjects Enrolled in the Study.
Case–Control Series Country Region or City
Case Subjects 
(N = 4866)
Control Subjects 
(N = 3536) Reference
number
Kenyan Bacteremia Study Kenya Kilifi coastal area 770 560* Berkley et al.20
Malawian Tuberculosis Study Malawi Karonga District 335 450 Crampin et al.21
Hong Kong Tuberculosis Study China Hong Kong city 907 784 Tang et al.22
Gambian Tuberculosis Study Gambia Banjul coastal area 1309 1427 Lienhardt et al.23
Gambian Malaria Study Gambia Banjul coastal area 485 210 Hill et al.24
Kenyan Malaria Study Kenya Kilifi coastal area 685 560* Marsh et al.25
Vietnam Malaria Study Vietnam Ho Chi Minh City 375 105 Khor et al.8
* Shared controls were used for the Kenyan Bacteremia Study and the Kenyan Malaria Study.8
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for the potential confounding effects of age, sex, 
and race or ethnic group did not affect the de-
gree of statistical significance or odds ratio for 
each SNP. The trend test also showed an increase 
in the risk of disease with an increase in the 
number of risk alleles (P = 0.03) (see the Supple-
mentary Appendix). In the Hong Kong Tubercu-
losis Study, persons with tuberculosis were more 
likely to carry variant CISH alleles (at positions 
−292 and +1320) than were unaffected persons 
(P = 0.03 and P = 2.0×10−3, respectively). In the 
case–control Gambian Tuberculosis Study, we 
observed an association between the CISH +1320 
variant allele (but not the −292 SNP variant al-
lele) and susceptibility to clinical tuberculosis 
(P = 0.03). The positive trend test for tuberculosis 
observed in the Malawian Tuberculosis Study was 
replicated in both the Hong Kong Tuberculosis 
Study (P = 0.01) and the Gambian Tuberculosis 
Study (P = 0.03).
We genotyped the five CISH SNPs in three 
sample collections obtained from subjects with 
severe malaria in the Gambian Malaria Study, 
the Kenyan Malaria Study, and the Vietnam Ma-
laria Study. The variant alleles at positions −639, 
−292, +1320, and +3415 showed a significant as-
sociation with increased susceptibility to disease. 
In particular, the minor allele at position −292 
showed a significant association with suscepti-
bility to severe malaria in the Gambian Malaria 
Study, the Kenyan Malaria Study, and the small-
er Vietnam Malaria Study (Table 2). The trend 
toward an increase in disease risk with an in-
creasing number of CISH risk alleles observed in 
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Figure 1. Single-Nucleotide Polymorphisms Genotyped within CISH and Its 2-Mb Flanking Region.
CISH is highlighted in gray. The dashed horizontal line indicates a P value of 0.05. P values are for the association with disease risk.
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the bacteremia and tuberculosis studies was 
replicated in all three malaria studies (see the 
Supplementary Appendix).
To investigate the possibility that the associ-
ated SNPs might be in linkage disequilibrium 
with causative variants, we performed exclusion 
mapping by genotyping 28 additional SNPs span-
ning 2 million bp in the chromosome 3p21 re-
gion surrounding CISH in the Malawian Tuber-
culosis Study population. None of these 28 SNPs 
showed evidence of association with tuberculo-
sis (Fig. 1).
On pooled analysis, the carriage of CISH risk 
alleles at −639, −292, −163, +1320, and +3415 
was associated with increased susceptibility to 
the infectious diseases studied (Table 2), with 
Table 2. Results of Single-Nucleotide Polymorphism (SNP) Analysis of CISH.*
SNP and Study 
Population
No. of 
Subjects
Best-Fitting 
Genetic Model Risk-Allele Frequency† Combined Analysis
Case 
Subjects
Control 
Subjects P Value
Odds Ratio 
(95% CI) P Value‡
Odds Ratio 
(95% CI)
−639
KB 1326 Allelic 0.06 0.04 0.007 1.64 (1.14–2.35)
MTB 607 Allelic 0.04 0.02 0.11 1.76 (0.87–3.53)
HKTB — — — — — —
GTB 2690 Allelic 0.02 0.02 0.88 1.03 (0.68–1.57) 1.8×10−4 1.49 (1.22–1.83)
KM 1212 Allelic 0.06 0.04 0.02 1.57 (1.08–2.28)
GM 660 Allelic 0.03 0.02 0.09 2.11 (0.87–5.11)
VM — — — — — —
−292
KB 1293 Allelic 0.41 0.35 0.001 1.31 (1.11–1.55)
MTB 749 Allelic 0.45 0.39 0.01 1.30 (1.06–1.61)
HKTB 1677 Allelic 0.41 0.37 0.03 1.17 (1.01–1.34)
GTB 2696 Allelic 0.28 0.28 0.81 0.99 (0.88–1.11) 4.6×10−7 1.19 (1.12–1.25)
KM 1174 Allelic 0.39 0.35 0.04 1.19 (1.01–1.41)
GM 675 Allelic 0.28 0.22 0.03 1.36 (1.03–1.78)
VM 471 Dominant 0.41 0.34 0.03 1.60 (1.01–2.52)
−163
KB 1204 Allelic 0.17 0.12 0.002 1.50 (1.16–1.95)
MTB 629 Allelic 0.16 0.14 0.23 1.21 (0.88–1.68)
HKTB 1616 Allelic 0.17 0.18 0.45 0.93 (0.76–1.13)
GTB§ 2690 Allelic 0.20 0.19 0.64 1.04 (0.88–1.22)
KM 1145 Allelic 0.24 0.12 <0.001¶ 2.20 (1.72–2.84)
GM 649 Allelic 0.13 0.12 0.58 1.11 (0.76–1.63)
VM — — — — — —
+1320
KB 1200 Allelic 0.16 0.16 0.99 1.00 (0.74–1.35)
MTB 819 Recessive 0.17 0.16 0.005 2.99 (1.27–7.18)
HKTB 1691 Allelic 0.36 0.31 0.002 1.25 (1.08–1.44)
GTB 2736 Allelic 0.06 0.05 0.03 1.28 (1.02–1.62) 6.1×10−4 1.17 (1.07–1.28)
KM 1024 Allelic 0.16 0.16 0.99 1.00 (0.78–1.28)
GM 689 Allelic 0.06 0.03 0.02 1.98 (1.09–3.57)
VM 479 Allelic 0.33 0.31 0.58 1.10 (0.79–1.53)
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−292 accounting for most of the association sig-
nal (P = 4.58×10−7) (Table 2 and Fig. 2). Multiple-
SNP scoring of the five SNPs in each case–con-
trol study revealed a correlation between the 
number of CISH risk alleles and the risk of dis-
ease (P = 3.8×10−11 for trend) (see the Supplemen-
tary Appendix). In persons carrying one or more 
risk alleles, the overall risk was increased by at 
least 18%.
Functional Analysis of CISH
We studied the functional effects of the CISH pro-
moter variants because these SNPs showed the 
strongest associations with disease and they are 
more likely to affect gene expression than intra-
genic SNPs. We genotyped the promoter SNPs at 
positions −639, −292, and −163 in 400 healthy 
adult subjects of Han Chinese descent. The ob-
served risk-allele frequency for the SNPs at posi-
tions −292 and −163 was 41.5% and 6.1%, respec-
tively, and only a single subject was homozygous 
for the variant allele at position −163; SNP −639 
was not polymorphic in these persons, a finding 
that is consistent with observations from the 
Hong Kong Chinese case–control study. We first 
examined the individual effects of SNPs −292 
and −163 on CISH gene expression in human PB-
MCs after stimulation with interleukin-2 at a fi-
nal concentration of 100 U per milliliter. Since 
levels of expression of the wild-type CISH −292AA 
and carrier CISH −292AT genotypes did not differ 
significantly, we questioned whether this SNP 
might exert a recessive effect. As shown in Figure 
3A, the 10 persons who were homozygous for the 
variant CISH −292TT risk genotype had signifi-
cantly lower levels of CISH than the 5 persons 
who were homozygous for the alternative allele 
(AA) and the 10 heterozygous carriers (AT) at 30, 
60, and 120 minutes after stimulation with inter-
leukin-2. We did not observe any difference in 
CISH expression (with respect to the CISH −292 
genotype) after stimulation with interleukin-3. 
Nor did we observe a significant genotype-spe-
cific difference according to allelic variation at 
position −163 after stimulating cells with either 
interleukin-2 or interleukin-3 (data not shown).
To test for an interactive effect between CISH 
−292 and CISH −163, we determined two SNP 
Table 2. (Continued.)
SNP and Study 
Population
No. of 
Subjects
Best-Fitting 
Genetic Model Risk-Allele Frequency† Combined Analysis
Case 
Subjects
Control 
Subjects P Value
Odds Ratio 
(95% CI) P Value‡
Odds Ratio 
(95% CI)
+3415
KB 1257 Allelic 0.24 0.20 0.02 1.26 (1.04–1.53)
MTB 780 Allelic 0.29 0.24 0.04 1.27 (1.01–1.59)
HKTB 1677 Allelic 0.06 0.06 0.31 0.86 (0.65–1.15)
GTB 2702 Allelic 0.22 0.22 0.96 1.00 (0.88–1.13) 0.01 1.11 (1.03–1.20)
KM 1189 Allelic 0.24 0.20 0.04 1.23 (1.01–1.50)
GM 684 Allelic 0.23 0.21 0.26 1.18 (0.89–1.56)
VM 478 Allelic 0.06 0.05 0.63 1.19 (0.59–2.42)
* Dashes indicate that the marker was not polymorphic in the specific population. GM denotes Gambian Malaria Study, GTB Gambian Tuber-
culosis Study, HKTB Hong Kong Tuberculosis Study, KB Kenyan Bacteremia Study, KM Kenyan Malaria Study, MTB Malawian Tuberculosis 
Study, and VM Vietnam Malaria Study.
† The risk-allele frequency is the minor-allele frequency for each SNP genotyped. This value is the actual allelic frequency and not the result of 
prediction programs. It was calculated as the number of mutant alleles divided by the total number of alleles.
‡ Both the Tarone and Breslow–Day tests for homogeneity showed no significant differences across the study populations for CISH −639, 
−292, and +3415, indicating that the pooled odds ratio and accompanying pooled P value were applicable across all populations. However, 
for CISH −292, inclusion of the GTB data resulted in tests of homogeneity that showed borderline significance (P = 0.06). Thus, we performed a 
secondary analysis for −292, which did not include the GTB data (P = 3.9×10−8; odds ratio, 1.23; 95% CI, 1.19 to 1.34).
§  The Tarone and Breslow–Day tests for homogeneity showed marked significance (P<0.001) for CISH −163; thus, pooling should not be per-
formed for this SNP. However, for pooling performed for the sake of information, P = 3.0×10−7.
¶ Since this was an apparently highly significant single-point observation, we confirmed the concordance of genotype calls between two inves-
tigators who were unaware of the case–control assignments. The concordance rate was 100%, arguing against genotyping error as the 
cause of this observation.
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diplotypes, −292 and −163, for the subjects in 
whom CISH expression was assessed (with the 
chromosomal phase determined by subcloning 
and sequencing for persons with a chromosomal 
phase that was uncertain), and we then compared 
CISH expression between the −292 genotypes in 
response to interleukin-2 stimulation, using −163 
as the conditioning locus. For persons who were 
homozygous for the major (nonrisk) allele at 
−163, carriage of the variant −292TT genotype 
resulted in markedly lower overall gene expres-
sion (25 to 40% lower) in response to interleu-
kin-2 stimulation at all time points (Fig. 3B). We 
observed no significant differences in CISH ex-
pression after stimulation by interleukin-2 or 
interleukin-3 when we compared the other CISH 
diplotypes with one another (data not shown).
Discussion
We identified a panel of five CISH SNPs associat-
ed with increased susceptibility to bacteremia, 
tuberculosis, and malaria, and we estimated that 
the overall risk of one of these infectious diseases 
was increased by 18% among persons carrying a 
single CISH “risk” allele. This risk increased to 
81% among persons with four or more risk al-
leles (see the Supplementary Appendix).
Two important considerations in genetic as-
sociation studies are population stratification and 
multiple testing. To assess the presence of popu-
lation stratification, we examined 28 indepen-
dent markers in the 2-Mb region flanking CISH, 
and we did not detect significant inflation of test 
statistics (genomic inflation factor, 1.03). Further-
more, the consistency of the association across 
multiple racial and ethnic groups argues against 
the results being a product of population stratifi-
cation. To account for multiple testing, we evalu-
ated CISH in the context of 20 other immune-
related genes (analyzing a total of 187 SNPs) 
previously tested in one or more of these sample 
collections (see the Supplementary Appendix); 
the single-point observation with CISH −292 
(P = 4.58×10−7) remained significant after correc-
tion for all the genes and SNPs tested (the thresh-
old P value after correction for multiple testing 
is 10−4, with each of the 187 SNPs tested on aver-
age 2.7 times). The false positive report probabil-
ity29 for −292 was 10−4 or less even at previous 
probability levels of 10−5 or less. Further confi-
dence is lent by the very low P value (<5×10−11) 
observed with the multiple-SNP score and the 
level of replication among study groups.
The pattern of association with CISH −292 was 
consistently reproducible across six of the seven 
study groups, with the exception of the Gambian 
Tuberculosis Study. One possible explanation for 
this heterogeneity is that disease susceptibility 
was accounted for by more than one SNP within 
the five-SNP panel, thus rendering the single-SNP 
analysis incomplete. A second reason might re-
late to the underlying population structure, where 
different CISH SNPs may tag the informative vari-
ants in each distinct population. A third possibil-
ity is that there remain unidentified functional 
SNPs within the region of association delineated 
by the five-SNP panel that also account for asso-
ciation with disease. This last possibility is un-
likely, however, since direct sequencing did not 
detect additional putatively functional polymor-
phisms. To explore the first and second possi-
bilities, we used multiple-SNP scoring for all five 
associated SNPs. The risk of disease increased 
markedly with an increase in the number of risk 
alleles carried in each population. Since this 
multiple-SNP analysis was more informative, with 
respect to risk, than analyses of single SNPs in 
isolation, the first two possibilities remain plau-
sible explanations. The mechanisms underlying 
2.51
Kenyan Bacteremia Study
Malawian Tuberculosis Study
Hong Kong Tuberculosis Study
Gambian Tuberculosis Study
Gambian Malaria Study
Kenyan Malaria Study
Vietnam Malaria Study
Combined analysis
Combined analysis
without Gambian 
Tuberculosis Study
Odds Ratio (95% CI)
Subgroup
0.79 0.89 1.00 1.12 1.26 1.41 1.58 1.78 2.242.00
Figure 2. Odds Ratio for the Variant Allele CISH −292, According to Study 
Population.
Results of the overall pooled analysis and case–control analyses were gener-
ated with the use of the allelic test. The oblongs represent point estimates, 
with the height of the oblongs inversely proportional to the standard error 
of the estimate. The horizontal lines indicate the 95% confidence intervals 
for the estimates. The diamonds represent the summary odds ratios, with 
the width indicating the 95% confidence interval.
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an association between the CISH multiple-SNP 
score and the accompanying dose-dependent ef-
fect on disease susceptibility probably reflect the 
potential regulatory effect of these polymor-
phisms within a “multiple-hit model,” whereby 
each “hit” affects gene expression cumulatively 
in aggregate. Such a process contrasts with that 
of structural variants, in which the presence of 
one deleterious mutation may be sufficient to 
account for disease.
In the ex vivo study, carriage of the −292 allele 
reduced CISH expression after stimulation with 
interleukin-2. However, this study lacked power 
to detect significant differences in gene expres-
sion in persons with 0, 1, 2, 3, and 4 or more 
risk alleles. Although −292 showed associations 
with multiple infectious diseases and could be a 
true functional variant, +1320 showed a stronger 
association with susceptibility to tuberculosis, 
and we found this association in each of the 
tuberculosis studies. Perhaps variation at +1320 
affects transcript expression; position +1320 is 
located in the untranslated portion of exon 2.30
Stimulation by interleukin-2 may enhance 
microbial and viral replication,31 and its effect 
may be further dependent on the presence of 
other immune cells. For example, clinical trials 
of interleukin-2 infusion in HIV-positive patients 
have shown different effects on individual per-
sons depending on their CD4+ counts.32,33 Al-
though it is perhaps unexpected that common 
variation within a single gene influences suscep-
tibility to a diverse range of infectious diseases, 
there is increasing evidence that disparate infec-
tions are recognized by a common host inflam-
matory pathway.8,34-36
The observation that the risk alleles occur at 
appreciable allele frequencies in each of the study 
populations is surprising, given data that sug-
gest an evolutionary selective pressure exerted by 
some infectious diseases.37,38 One explanation 
may be that the variant alleles associate with 
decreased susceptibility against other major 
causes of death in these populations. For exam-
ple, immune modulation at the interleukin-2 re-
ceptor axis may protect against type 1 diabetes 
mellitus.39 A possible role of CISH polymorphisms 
in the development of inflammatory as well as 
infectious diseases merits further study.
Current clinical management of bacteremia, 
malaria, and tuberculosis relies primarily on anti-
microbial agents that are specifically targeted to 
the likely pathogen. Our findings implicate CISH 
in multiple-pathogen susceptibility and raise the 
possibility that pharmacologic manipulation of 
the SOCS pathway may have an effect on the 
treatment of multiple, diverse infectious diseases. 
CISH variants may also influence responses to 
existing immunotherapies such as interleukin-2 
therapy in renal-cell cancer, which is associated 
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Figure 3. Expression of CISH −292 in Response 
to  Stimulation with Interleukin-2.
Panel A shows differential expression of 5 wild-type (AA), 
10 heterozygous (AT), and 10 homozygous mutant (TT) 
forms of CISH −292 in response to interleukin-2 stimu-
lation. Panel B shows differential expression of five wild-
type (AC/AC), five heterozygous (AC/TC), and five homo-
zygous mutant (TC/TC) forms of the CISH −292 −163 
diplotype in response to interleukin-2 stimulation in per-
sons who were homo zygous for the wild-type form at 
the −163 locus. I bars indicate standard errors.
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with wide and largely unexplained variations in 
interindividual response rates.40,41 Study of longi-
tudinal immune responses together with re-
sponses to antimicrobial agents and clinical 
outcome in patients with infectious diseases 
may further define the risk model for CISH SNPs. 
The integration of such a model with environ-
mental and other host genetic factors may im-
prove the prediction of treatment responses and 
disease outcomes.
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